Skip to main content

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights

Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer

Multiple Myeloma, Oncology

ASCO 2017: Multiple Myeloma Highlights

Novel Drug “Home Run” for TRK Mutation–Positive Tumors

Maintenance Treatment in Mantle-Cell Lymphoma Extends Survival

Immunotherapy, Oncology

Adoptive T-Cell Therapy: Ready for Prime Time

Less Is More: Low-Risk Stage III Colon Cancer Safely Treated with Only 3 Months of Adjuvant Chemotherapy

Practice Management

Oncologists Must Begin to Discuss Financial Toxicity with Patients

Page 3 of 3
Results 21 - 27 of 27